Ambagon Therapeutics
953 Indiana St
San Francisco
CA
94107
United States
5 articles about Ambagon Therapeutics
-
BioSpace is proud to present its NextGen Bio “Class of 2023,” a list of the hottest recently launched life sciences companies in North America.
-
After reaching a record high in 2021, venture capital dollars have tailed off in the biopharma industry in 2022. That said, a few biopharma hotbeds have still seen sizeable launch rounds.
-
Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board
4/26/2022
Ambagon Therapeutics today announced the appointment of Gideon Bollag, Ph.D., to its Scientific Advisory Board.
-
Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
1/6/2022
Ambagon Therapeutics today announced an $85 million Series A to augment its drug discovery platform and to advance its pipeline of molecular glues.
-
Ambagon Therapeutics closes its first financing round with $85 million. The Series A funds will help advance the company's drug discovery platform and molecular glue pipeline.